Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort
Authors:
- Eva H. van der GeestEGEva H. van der Geest
- Nina Ajmone MarsanNina Ajmone Marsan
- Dorien LaenensDLDorien Laenens
- Philippe J. M. R. DebonnairePDPhilippe J. M. R. Debonnaire
- Mathias ClaeysMCMathias Claeys
- Fauto PintoFauto Pinto
- Dulce BritoDBDulce Brito
- Erwan DonalEDErwan Donal
- Steven DroogmansSDSteven Droogmans
- Nico Van de VeireNVNico Van de Veire
- Philippe BertrandPBPhilippe Bertrand
- Takeru NabetaTNTakeru Nabeta
Open Access
- 11 October 2025
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (10) , 403
Abstract
Background: Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort. Methods: A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divided based on guideline publication dates. Results: Patients were predominantly male (73.2%) with a median age of 78 years. Prescription of diuretics (52.8%) and disease-modifying therapy (44.9%), mostly tafamidis, was common. BBs (43.7%) and ACEi/ARBs (41.2%) were prescribed more often in patients with higher NYHA class, elevated NT-proBNP, and more comorbidities. Blood pressure and heart rate were similar regardless of BB or ACEi/ARB use. BB prescription and combination therapy with BB and ACEi/ARB increased over time. Neither BB nor ACEi/ARB use significantly impacted mortality when analyzed in a multivariate Cox proportional hazard regression. Conclusions: Use of BBs and ACEi/ARBs has increased over time, particularly in advanced-stage ATTR-CA patients, and although these therapies appear to be reasonably tolerated, survival was not significantly altered.Keywords
All Related Versions
Funding Information
- Alnylam Pharmaceuticals
- Pfizer
This publication has 22 references indexed in Scilit:
- Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosisHeart Rhythm, 2024
- Effect of Beta-Blockade on Mortality in Patients with Cardiac Amyloidosis: A Systematic Review and Meta-AnalysisESC Heart Failure, 2024
- SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyJACC, 2024
- Contemporary Guideline-Directed Medical Therapy in De Novo, Chronic, and Worsening Heart Failure Patients: First Data from the TITRATE-HF StudyEuropean Journal of Heart Failure, 2024
- Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionJACC, 2024
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac AmyloidosisJACC, 2023
- Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fractionRevista Portuguesa de Cardiologia, 2022
- Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid CardiomyopathyMayo Clinic Proceedings, 2022
- Safety and Tolerability of Neurohormonal Antagonism in Cardiac AmyloidosisEuropean Journal of Internal Medicine, 2020
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018